Exelixis (NASDAQ:EXEL) perks up 1% premarket on light volume on the heels of results from an open-label Phase 1/2 clinical trial, CheckMate 040, evaluating the combination of Cabometyx (cabozantinib) and Bristol-Myers Squibb’s (NYSE:BMY)
Opdivo (nivolumab), with or without Yervoy (ipilimumab), in patients
with advanced hepatocellular carcinoma (HCC). The data are being
presented today at the ASCO GI Cancers Symposium in San Francisco.
In treatment-naïve patients receiving cabozantinib
and nivolumab (n=17) and those receiving prior treatment with Bayer’s
Nexavar (sorafenib) (n=19), the objective response rate (ORR) was 19%
and the disease control rate (responders + stable cancer) was
75%. Median progression-free survival (PFS) was 5.4 months while median
overall survival (OS) was 21.5 months.
In 35 patients receiving cabozantinib, nivolumab
and ipilimumab (12 treatment-naïve), including 23 with prior sorafenib
therapy, ORR was 29%, DCR was 83% and median PFS was 6.8 months. Median
OS had not been reached at data cutoff.
No new safety signals were observed.
https://seekingalpha.com/news/3534313-exelixis-up-1-premarket-on-cabometyx-data-in-liver-cancer
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.